Timothy Eugene Sullivan

This profile gathers the share dealings of Timothy Eugene Sullivan in Apellis Pharmaceuticals, Inc., where the filings describe the role as finance chief. Between 29 August 2019 and 14 May 2026, the trades on record add up to 46 filings.

The open-market side counts 1 purchase for €314k alongside 14 sales for €6.7M. The net balance comes to €6.4M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 15 share grants and 9 option exercises. In 2026 alone, the filings show no purchases and 3 sales.

On 14 May 2026 came the latest disclosure, a transaction in Apellis Pharmaceuticals, Inc. The most recent open-market purchase was published on 3 September 2019, 2,607 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.